Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 -4.58%29 PS Ratio is 20,833.33 as of Jul. 20, 2026, which is 135% above its 10-year median of 8,850.00. GuruFocus rates ROCO:6586 with a GF Score™ of 29/100. The stock has 4 warning signs investors should review. Among 931 Biotechnology companies, CHO Pharma ranks worse than 99.57% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CHO Pharma's share price is NT$125.00.
CHO Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.01. Hence, CHO Pharma's PS Ratio for today is 20,833.33.
Warning Sign:
CHO Pharma Inc stock PS Ratio (=17857.14) is close to 3-year high of 18285.71.
The historical rank and industry rank for CHO Pharma's PS Ratio or its related term are showing as below:
ROCO:6586'
s PS Ratio Range Over the Past 10 Years
Min: 1652.94 Med: 8850 Max: 92200
Current: 20833.33
During the past 13 years, CHO Pharma's highest PS Ratio was 92200.00. The lowest was 1652.94. And the median was 8850.00.
ROCO:6586's PS Ratio is ranked worse than 99.57% of 931
companies
in the Biotechnology industry
Industry Median: 9.32
vs ROCO:6586: 20833.33
During the past 13 years, CHO Pharma's highest 3-Year average Revenue per Share Growth Rate was 111.80% per year. The lowest was -43.30% per year. And the median was -12.10% per year.
Back to Basics: PS Ratio
CHO Pharma (ROCO:6586) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CHO Pharma PS Ratio Related Terms
CHO Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for CHO Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, CHO Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where CHO Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CHO Pharma's Share Price of today is NT$125.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CHO Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CHO Pharma (ROCO:6586) has a PS Ratio of 20,833.33 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CHO Pharma and its competitors. This is 135% above median its historical median of 8,850.00. Over the past decade, CHO Pharma's PS Ratio has ranged from 1,652.94 to 92,200.00. According to the industry distribution chart, CHO Pharma ranks #927 out of 931 companies in the Biotechnology industry, placing it in the top 99.6%.
Is CHO Pharma's PS Ratio too high?
CHO Pharma's current PS Ratio of 20,833.33 is 135% above median its 10-year median of 8,850.00. Over the past 10 years, this metric has ranged from a low of 1,652.94 to a high of 92,200.00. The Biotechnology industry median PS Ratio is 9.32. CHO Pharma's value of 20,833.33 is 223433.6% above this industry median. Based on the distribution chart, CHO Pharma ranks #927 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CHO Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #927 out of 931 companies for PS Ratio. This places CHO Pharma in the lower half of its industry. The industry median PS Ratio is 9.32. CHO Pharma's value of 20,833.33 is 223433.6% above this benchmark. Historically, CHO Pharma's own PS Ratio has ranged from 1,652.94 to 92,200.00 over the past decade. While the company's 10-year median is 8,850.00 vs. the industry median of 9.32, CHO Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.32, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHO Pharma's current PS Ratio of 20,833.33 is 223433.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CHO Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHO Pharma's current PS Ratio is 20,833.33, which is 135% above median its own 10-year median of 8,850.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current PS Ratio of 20,833.33. The current PS Ratio is 20,833.33, which is 135% above median its 10-year median of 8,850.00 and 223433.6% above the Biotechnology industry median of 9.32. CHO Pharma's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current PS Ratio is 20,833.33 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
29GF Score
Get the complete analysis for ROCO:6586
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
